Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 2:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lybrel Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens

NCT00117273
View directory record Official record
Conditions
Healthy
Interventions
Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)], Seasonique (LNG/EE and EE), Portia (LNG/EE)
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 7, 2026, 2:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Oral Contraceptive Efficacy and Body Weight

NCT00662454
View directory record Official record
Conditions
Contraception, Body Weight
Interventions
ethinyl estradiol / levonorgestrel
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Sep 7, 2026, 2:35 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain

NCT00196365
View directory record Official record
Conditions
Dysmenorrhea
Interventions
levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets, levonorgestrel/EE 0.15/0.03 mg tablets and placebo
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
Huntsville, Alabama • Phoenix, Arizona • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 11, 2014 · Synced Sep 7, 2026, 2:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Multicenter Study to Evaluate the Effects of a 91-day Oral Contraceptive on Bone Mineral Density in Adolescent Females

NCT00924560
View directory record Official record
Conditions
Bone Mineral Density
Interventions
91-day Levonorgestrel Oral Contraceptive, 28-day Levonorgestrel Oral Contraceptive
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
12 Years to 18 Years · Female only
Enrollment
1,361 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
46
States / cities
Phoenix, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2014 · Synced Sep 7, 2026, 2:35 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

NCT07190430
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-08049820, Midazolam, Dabigatran Etexilate, Portia (EE and LN) or equivalent oral tablet
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 7, 2026, 2:35 PM EDT
Completed Phase 2 Interventional Results available

A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches

NCT00781456
View directory record Official record
Conditions
Migraine
Interventions
91-day Levonorgestrel Oral Contraceptive, Placebo
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 34 Years · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
22
States / cities
La Mesa, California • San Diego, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2017 · Synced Sep 7, 2026, 2:35 PM EDT
Withdrawn Phase 4 Interventional

Changes in Oral Contraceptive Hormones After Gastric Bypass Surgery

NCT01941134
View directory record Official record
Conditions
Bariatric Surgery Candidate, Contraception
Interventions
ethinyl estradiol-levonorgestrel
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Sep 7, 2026, 2:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AZD6140 Oral Contraceptive Interaction Study

NCT00685906
View directory record Official record
Conditions
Healthy
Interventions
AZD6140, Levonorgestrel and Ethinyl Estradiol (Nordette®)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 1, 2010 · Synced Sep 7, 2026, 2:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants

NCT07502417
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Ethinyl Estradiol + Levonorgestrel, ABBV-722
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 7, 2026, 2:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation

NCT02922127
View directory record Official record
Conditions
Contraception
Interventions
Ulipristal Acetate, Combined Oral Contraceptive Pill
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Sep 7, 2026, 2:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS

NCT05093205
View directory record Official record
Conditions
Healthy Adults
Interventions
PF-06882961, Atorvastatin, Midazolam, Levonorgestrel & Ethinyl Estradiol
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 7, 2026, 2:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants

NCT06942936
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD5004, Itraconazole, EE/LNG
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 7, 2026, 2:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects

NCT03662516
View directory record Official record
Conditions
Healthy Females
Interventions
PF-04965842, Ethinyl estradiol (EE) and levonorgestrel (LN)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 22, 2020 · Synced Sep 7, 2026, 2:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Oral Contraceptives and Body Mass Index

NCT01170390
View directory record Official record
Conditions
Body Weight, Contraceptive Usage
Interventions
All participants (Aviane), Portia, Aviane
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Sep 7, 2026, 2:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women

NCT01252186
View directory record Official record
Conditions
Hemostasis, Oral Contraceptive
Interventions
91-day Levonorgestrel Oral Contraceptive, 28-day Levonorgestrel Oral Contraceptive, 28-day Desogestrel Oral Contraceptive
Drug
Lead sponsor
Teva Women's Health
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
265 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
21
States / cities
San Diego, California • Washington D.C., District of Columbia • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2015 · Synced Sep 7, 2026, 2:35 PM EDT
Not listed Phase 1 Interventional

A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies

NCT03557619
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Venetoclax, ethinyl estradiol/levonorgestrel
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
3
States / cities
Detroit, Michigan • Lebanon, New Hampshire • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Sep 7, 2026, 2:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale

NCT00394771
View directory record Official record
Conditions
Breakthrough Bleeding
Interventions
DR-1031, Seasonale®, Portia®
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
567 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
50
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Sep 7, 2026, 2:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions

NCT06671405
View directory record Official record
Conditions
Dyslipidaemia
Interventions
AZD0780, Itraconazole, Carbamazepine, Midazolam, Ethinyl estradiol/levonorgestrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 7, 2026, 2:35 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of Pregnancy

NCT00996580
View directory record Official record
Conditions
Pregnancy Prevention
Interventions
DR-103
Drug
Lead sponsor
Teva Women's Health
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
3,597 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
94
States / cities
Montgomery, Alabama • Phoenix, Arizona • Tucson, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Sep 7, 2026, 2:35 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)

NCT07539090
View directory record Official record
Conditions
Healthy Participants
Interventions
Vimseltinib, Combined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG])
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 7, 2026, 2:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Effect of ITCA 650 on the PK/PD of Oral Contraceptive in Healthy Female Subjects

NCT02641990
View directory record Official record
Conditions
Healthy Adult Premenopausal Female Volunteers
Interventions
ITCA 650 20/60 mcg/day, ITCA placebo, ITCA placebo, ITCA 650 20/60 mcg/day
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Sep 7, 2026, 2:35 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Contraceptive Hormone and Reward Measurement (CHARM Study)

NCT05058872
View directory record Official record
Conditions
Oral Hormonal Contraceptive Use, Neural Activity, Mood, Hedonic Function
Interventions
Levonorgestrel/ethinyl estradiol, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Female only
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 3, 2024 · Synced Sep 7, 2026, 2:35 PM EDT
Completed Phase 1 Interventional

Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients

NCT03630159
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Tisagenlecleucel, Pembrolizumab
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia • Chicago, Illinois • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2022 · Synced Sep 7, 2026, 2:35 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Multicenter Study to Evaluate the Safety of Seasonique, an Oral Contraceptive.

NCT00196352
View directory record Official record
Conditions
Contraception
Interventions
Levonorgestrel/EE 0.15/0.03 mg and EE 0.01 mg tablets
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
11
States / cities
Tucson, Arizona • Washington D.C., District of Columbia • Lincoln, Nebraska + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Sep 7, 2026, 2:35 PM EDT